Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · see citing works

The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis

Kluck, R. M., Bossy‐Wetzel, E., Green, D. R., & Newmeyer, D. D. (1997) · Science · doi:10.1126/science.275.5303.1132 · Cited by 4,715 · see citing works

Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death

Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988 · see citing works

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

Joensuu, H., Roberts‎, P., Sarlomo‐Rikala, M., Andersson, L. C., Tervahartiala, P. O., Tuveson, D. A., Silberman, S., Capdeville, R., Dimitrijević, S., Druker, B. J., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,030 · see citing works

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,748 · see citing works

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677 · see citing works

Chronic Myeloid Leukemia

Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,615 · see citing works

The BCL-2 Family Reunion

Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,432 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278 · see citing works

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works

The cancer biomarker problem

Sawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 973 · see citing works

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708 · see citing works

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T. T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P. G. G., Tai, Y., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 588 · see citing works

BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents

Deng, J., Carlson, N. E., Takeyama, K., Cin, P. D., Shipp, M. A., & Letai, A. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.001 · Cited by 509 · see citing works

Circumventing cancer drug resistance in the era of personalized medicine

Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503 · see citing works

Inconsistency in large pharmacogenomic studies

Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499 · see citing works

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348 · see citing works

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Faber, A. C., Li, D., Song, Y., Liang, M., Yeap, B. Y., Bronson, R. T., Lifshits, E., Zhao, C., Maira, S.-M., Garcı́a-Echeverrı́a, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 315 · see citing works

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0103 · Cited by 294 · see citing works

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283 · see citing works

Functional proteomic profiling of AML predicts response and survival

Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W., Kantarjian, H. M., Andreeff, M., Coombes, K. R., & Mills, G. B. (2008) · Blood · doi:10.1182/blood-2007-10-119438 · Cited by 265 · see citing works

Elucidating Distinct Roles for <i>NF1</i> in Melanomagenesis

Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258 · see citing works

BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

Sarosiek, K. A., Chi, X., Bachman, J. A., Sims, J. J., Montero, J., Patel, L., Flanagan, A., Andrews, D. W., Sorger, P. K., & Letai, A. G. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.048 · Cited by 247 · see citing works

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Ercan, D., Zejnullahu, K., Yonesaka, K., Xiao, Y., Capelletti, M., Rogers, A. M., Lifshits, E., Brown, A., Lee, C., Christensen, J. G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.526 · Cited by 229 · see citing works

BH3 profiling in whole cells by fluorimeter or FACS

Ryan, J. A., & Letai, A. G. (2013) · Methods · doi:10.1016/j.ymeth.2013.04.006 · Cited by 174 · see citing works

Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion

Deng, J., Shimamura, T., Perera, S. A., Carlson, N. E., Cai, D. D., Shapiro, G. I., Wong, K., & Letai, A. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1961 · Cited by 158 · see citing works

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

Bhatt, A. P., Bhende, P. M., Sin, S., Roy, D., Dittmer, D. P., & Damania, B. (2010) · Blood · doi:10.1182/blood-2009-10-251082 · Cited by 146 · see citing works

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Burstein, H. J., Mangu, P. B., Somerfield, M. R., Schrag, D., Samson, D. J., Holt, L., Zelman, D., & Ajani, J. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0354 · Cited by 139 · see citing works

Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4 + CD8 + thymocytes

Ryan, J. A., Brunelle, J. K., & Letai, A. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914878107 · Cited by 128 · see citing works

The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment

Yaffe, M. B. (2013) · Science Signaling · doi:10.1126/scisignal.2003684 · Cited by 67 · see citing works

Visualizing the Landscape of Selection Biomarkers in Current Phase III Oncology Clinical Trials

Sikorski, R. S., & Yao, B. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001087 · Cited by 8 · see citing works

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111 · see citing works

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · see citing works

BCL-2 proteins and apoptosis: Recent insights and unknowns

Edlich, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.190 · Cited by 631 · see citing works

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619 · see citing works

Precision medicine for cancer with next-generation functional diagnostics

Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570 · see citing works

A fate worse than death: apoptosis as an oncogenic process

Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451 · see citing works

Functional precision cancer medicine—moving beyond pure genomics

Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366 · see citing works

Mitochondria—Judges and Executioners of Cell Death Sentences

Bhola, P. D., & Letai, A. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.019 · Cited by 326 · see citing works

Why do BCL-2 inhibitors work and where should we use them in the clinic?

Montero, J., & Letai, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.183 · Cited by 325 · see citing works

Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts

Fior, R., Póvoa, V., Mendes, R. V., Carvalho, T., Gomes, A. P., Figueiredo, N., & Ferreira, M. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618389114 · Cited by 312 · see citing works

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295 · see citing works

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

Letai, A. G., Bhola, P. D., & Welm, A. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 282 · see citing works

Mechanism and regulation of pyroptosis-mediated in cancer cell death

Ruan, J., Wang, S., & Wang, J. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109052 · Cited by 274 · see citing works

Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death

Lu, H., Zhang, S., Wu, J., Chen, M., Cai, M., Fu, Y., Li, W., Wang, J., Zhao, X., Yu, Z., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1478 · Cited by 270 · see citing works

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Frismantas, V., Dobay, M. P., Rinaldi, A. M., Tchinda, J., Dunn, S. H., Kunz, J. B., Richter‐Pechańska, P., Marovca, B., Pail, O., Jenni, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738070 · Cited by 260 · see citing works

An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence

Dhimolea, E., Simoes, R. D. M., Kansara, D. N., Al’Khafaji, A. M., Bouyssou, J., Weng, X., Sharma, S., Raja, J., Awate, P., Shirasaki, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.002 · Cited by 260 · see citing works

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

Brasó‐Maristany, F., Filosto, S., Catchpole, S., Marlow, R., Quist, J., Francesch-Domenech, E., Plumb, D. A., Zakka, L., Gazińska, P., Liccardi, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4198 · Cited by 253 · see citing works

Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis

Lagares, D., Santos, A., Grasberger, P. E., Liu, F., Probst, C. K., Rahimi, R. A., Sakai, N., Kuehl, T., Ryan, J., Bhola, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3765 · Cited by 246 · see citing works

A microfluidics platform for combinatorial drug screening on cancer biopsies

Eduati, F., Utharala, R., Madhavan, D., Neumann, U. P., Longerich, T., Cramer, T., Saez-Rodriguez, J., & Merten, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04919-w · Cited by 239 · see citing works

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells

Kahn, J. D., Miller, P. G., Silver, A. J., Sellar, R. S., Bhatt, S., Gibson, C., McConkey, M., Adams, D., Mar, B., Mertins, P., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850339 · Cited by 225 · see citing works

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

Montero, J., Stephansky, J., Cai, T., Griffin, G. K., Cabal‐Hierro, L., Togami, K., Hogdal, L. J., Galinsky, I. A., Morgan, E. A., Aster, J. C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0999 · Cited by 215 · see citing works

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0538 · Cited by 206 · see citing works

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer

López, A., Reyna, D. E., Gitego, N., Kopp, F., Zhou, H., Miranda-Román, M. A., Nordstrøm, L. U., Narayanagari, S.-R., Chi, P., Vilar, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28741-7 · Cited by 203 · see citing works

Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway

Yang, Y., Liu, P. Y., Bao, W., Chen, S. J., Wu, F. S., & Zhu, P. (2020) · BMC Cancer · doi:10.1186/s12885-019-6491-6 · Cited by 202 · see citing works

A Physiological Function for Ferroptosis in Tumor Suppression by the Immune System

Stockwell, B. R., & Jiang, X. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.012 · Cited by 201 · see citing works

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis

Pan, R. A., Ryan, J. A., Pan, D., Wucherpfennig, K. W., & Letai, A. G. (2022) · Cell · doi:10.1016/j.cell.2022.03.030 · Cited by 199 · see citing works

Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia

Deng, J., Isik, E., Fernandes, S. M., Brown, J. R., Letai, A. G., & Davids, M. S. (2017) · Leukemia · doi:10.1038/leu.2017.32 · Cited by 198 · see citing works

Cancer Metabolism and the Evasion of Apoptotic Cell Death

Sharma, A., Boise, L., & Shanmugam, M. (2019) · Cancers · doi:10.3390/cancers11081144 · Cited by 189 · see citing works

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Bhatt, S., Pioso, M. S., Olesinski, E. A., Yilma, B., Ryan, J. A., Mashaka, T., Buon, L., Adamia, S., Zhu, H., Kuang, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.010 · Cited by 187 · see citing works

Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a pH-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy

Shen, S., Li, H., Chen, K., Wang, Y., Yang, X., Lian, Z., Du, J., & Wang, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01193 · Cited by 186 · see citing works

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

Snijder, B., Vladimer, G. I., Krall, N., Miura, K., Schmolke, A.-S., Kornauth, C., de la Fuente, O. L., Choi, H.-S., van der Kouwe, E., Gültekin, S., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30208-9 · Cited by 175 · see citing works

Targeting TBK1 to overcome resistance to cancer immunotherapy

Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05704-6 · Cited by 174 · see citing works

Targeting minimal residual disease: a path to cure?

Luskin, M. R., Murakami, M. A., Manalis, S. R., & Weinstock, D. M. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.125 · Cited by 172 · see citing works

Genomic evolution and chemoresistance in germ-cell tumours

Taylor-Weiner, A. N., Zack, T. I., O’Donnell, E., Guerriero, J. L., Bernard, B. D., Reddy, A. J., Han, G. C., AlDubayan, S. H., Amin‐Mansour, A., Schumacher, S. E., et al. (2016) · Nature · doi:10.1038/nature20596 · Cited by 169 · see citing works

Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia

de Beauchamp, L., Himonas, E., & Helgason, G. V. (2021) · Leukemia · doi:10.1038/s41375-021-01416-w · Cited by 168 · see citing works

Apoptosis and Cancer

Letai, A. G. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121933 · Cited by 163 · see citing works

The rise of apoptosis: targeting apoptosis in hematologic malignancies

Valentin, R., Grabow, S., & Davids, M. S. (2018) · Blood · doi:10.1182/blood-2018-02-791350 · Cited by 159 · see citing works

Targeting the Mevalonate Pathway in Cancer

Juarez, D., & Fruman, D. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.11.008 · Cited by 160 · see citing works

Inhibition of USP10 induces degradation of oncogenic FLT3

Weisberg, E., Schauer, N. J., Yang, J. C., Lamberto, I., Doherty, L. M., Bhatt, S., Nonami, A., Meng, C., Letai, A. G., Wright, R. D., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2486 · Cited by 142 · see citing works

Mitochondria and the hallmarks of cancer

Giampazolias, E., & Tait, S. W. G. (2015) · FEBS Journal · doi:10.1111/febs.13603 · Cited by 135 · see citing works

Mitochondrial levels determine variability in cell death by modulating apoptotic gene expression

Márquez-Jurado, S., Díaz‐Colunga, J., das Neves, R. P., Martinez-Lorente, A., Almazán, F., Guantes, R., & Iborra, F. J. (2018) · Nature Communications · doi:10.1038/s41467-017-02787-4 · Cited by 134 · see citing works

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

Matulis, S. M., Gupta, V. A., Nooka, A. K., Hollen, H. V., Kaufman, J. L., Lonial, S., & Boise, L. (2015) · Leukemia · doi:10.1038/leu.2015.350 · Cited by 132 · see citing works

iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry

Ryan, J. A., Montero, J., Rocco, J. W., & Letai, A. G. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0107 · Cited by 129 · see citing works

A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy

Amgalan, D., Garner, T., Pekson, R. C., Jia, X., Yanamandala, M., Paulino, V., Liang, F. G., Corbalán, J., Lee, J., Chen, Y., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0039-1 · Cited by 118 · see citing works

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126 · see citing works

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Wu, S.-C., Li, L. S., Kopp, N., Montero, J., Chapuy, B., Yoda, A., Christie, A. L., Liu, H., Christodoulou, A. N., van Bodegom, D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.005 · Cited by 123 · see citing works

TGFβ pathway inhibition in the treatment of non-small cell lung cancer

Eser, P. Ö., & Janne, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.004 · Cited by 116 · see citing works

STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment

Lohard, S., Bourgeois, N., Maillet, L., Gautier, F., Fétiveau, A., Lasla, H., Nguyen, F., Vuillier, C., Dumont, A., Moreau‐Aubry, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13689-y · Cited by 114 · see citing works

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

Watt, A. C., Cejas, P., DeCristo, M. J., Metzger-Filho, O., Lam, E., Qiu, X., BrinJones, H., Kesten, N., Coulson, R., Font-Tello, A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00135-y · Cited by 94 · see citing works

BCL-w: apoptotic and non-apoptotic role in health and disease

Hartman, M. L., & Czyż, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2417-0 · Cited by 107 · see citing works

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Stevens, M. M., Maire, C. L., Chou, N., Murakami, M. A., Knoff, D. S., Kikuchi, Y., Kimmerling, R. J., Liu, H., Haidar, S., Calistri, N. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3697 · Cited by 106 · see citing works

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

Bajpai, R., Sharma, A., Achreja, A., Edgar, C. L., Wei, C., Siddiqa, A., Gupta, V. A., Matulis, S. M., McBrayer, S. K., Mittal, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15051-z · Cited by 101 · see citing works

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells

Schroeder, B., Steen, T. V., Espinoza, I. C., Venkatapoorna, C. M. K., Hu, Z., Martín, F., Regan, K. M., Cuyàs, E., Meng, X. W., Verdura, S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04262-x · Cited by 100 · see citing works

Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition

Dey, J., Deckwerth, T. L., Kerwin, W. S., Casalini, J. R., Merrell, A., Grenley, M. O., Burns, C., Ditzler, S. H., Dixon, C., Beirne, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18368-w · Cited by 99 · see citing works

Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response

Park, D. E., Cheng, J., Berrios, C. J., Montero, J., Cortés-Cros, M., Ferretti, S., Arora, R., Tillgren, M. L., Gokhale, P. C., & DeCaprio, J. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818798116 · Cited by 99 · see citing works

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma

Mai, W. X., Gosa, L., Daniëls, V. W., Ta, L. H., Tsang, J., Higgins, B., Gilmore, W. B., Bayley, N. A., Harati, M. D., Lee, J. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4418 · Cited by 96 · see citing works

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL

Bojarczuk, K., Wienand, K., Ryan, J. A., Chen, L., Villalobos-Ortiz, M., Mandato, E., Stachura, J., Letai, A. G., Lawton, L. N., Chapuy, B., et al. (2018) · Blood · doi:10.1182/blood-2018-08-872465 · Cited by 96 · see citing works

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Song, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95 · see citing works

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94 · see citing works

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches

Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 93 · see citing works

BH3-dependent and independent activation of BAX and BAK in mitochondrial apoptosis

Jeng, P., Inoue‐Yamauchi, A., Hsieh, J. J.-D., & Cheng, E. H. Y. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.03.005 · Cited by 93 · see citing works

Statins enhance efficacy of venetoclax in blood cancers

Lee, J. S., Roberts, A. W., Juarez, D., Vo, T.-T. T., Bhatt, S., Herzog, L.-O., Mallya, S., Bellin, R. J., Agarwal, S. K., Salem, A. H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1240 · Cited by 93 · see citing works

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance

Togami, K., Pastika, T. J., Stephansky, J., Ghandi, M., Christie, A. L., Jones, K. L., Johnson, C. A., Lindsay, R. W. B., Brooks, C. L., Letai, A. G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128571 · Cited by 91 · see citing works

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Glytsou, C., Chen, X., Zacharioudakis, E., Al-Santli, W., Zhou, H., Nadorp, B., Lee, S., Lasry, A., Sun, Z., Papaioannou, D., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0601 · Cited by 86 · see citing works

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

Etchin, J., Montero, J., Berezovskaya, A., Le, B. T., Kentsis, A., Christie, A. L., Conway, A. S., Chen, W. C., Reed, C., Mansour, M. R., et al. (2015) · Leukemia · doi:10.1038/leu.2015.194 · Cited by 84 · see citing works

Zebrafish Avatars towards Personalized Medicine—A Comparative Review between Avatar Models

Costa, B. F., Estrada, M. F., Mendes, R. V., & Fior, R. (2020) · Cells · doi:10.3390/cells9020293 · Cited by 82 · see citing works

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80 · see citing works

Targeting MCL-1 protein to treat cancer: opportunities and challenges

Tantawy, S. I., Timofeeva, N., Sarkar, A. K., & Gandhi, V. V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 80 · see citing works

Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic

Shi, J., & Mitchison, T. J. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0003 · Cited by 79 · see citing works

Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach

Lee, D. J., & Zeidner, J. F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1678583 · Cited by 77 · see citing works

Five critical elements to ensure the precision medicine

Chen, C., He, M., Zhu, Y., Shi, L., & Wang, X. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9555-3 · Cited by 74 · see citing works

Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics

Montero, J., & Haq, R. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1334 · Cited by 73 · see citing works

Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection

Price, A. M., Dai, J., Bazot, Q., Patel, L., Nikitin, P. A., Djavadian, R., Winter, P. S., Salinas, C. A., Barry, A. P., Wood, K. C., et al. (2017) · eLife · doi:10.7554/elife.22509 · Cited by 73 · see citing works

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Boidol, B., Kornauth, C., van der Kouwe, E., Prutsch, N., Kazianka, L., Gültekin, S., Hoermann, G., Mayerhoefer, M. E., Hopfinger, G., Hauswirth, A. W., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785683 · Cited by 73 · see citing works

Simulation-assisted machine learning

Deist, T. M., Patti, A., Wang, Z., Krane, D., Sorenson, T., & Craft, D. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz199 · Cited by 73 · see citing works

Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer

Rodríguez-Hernández, M. A., de la Cruz‐Ojeda, P., López-Grueso, M. J., Navarro‐Villarán, E., Requejo-Aguilar, R., Castejón‐Vega, B., Negrete, M., Gallego, P., Vega-Ochoa, Á., Víctor, V. M., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101510 · Cited by 72 · see citing works

Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers

de la Rocha, A. A., Berlow, N., Fader, M. E., Coats, E. R., Saghira, C., Espinal, P. S., Galano, J., Khatib, Z. A., Abdella, H., Maher, O. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02848-4 · Cited by 72 · see citing works

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

Thummuri, D., Khan, S. U., Underwood, P. W., Zhang, P., Wiegand, J. S., Zhang, X., Budamagunta, V., Sobh, A., Tagmount, A., Loguinov, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0474 · Cited by 71 · see citing works

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

Tutusaus, A., Stefanović, M., Boix, L., Cucarull, B., Zamora, A. G., Blasco, L., de Frutos, P. G., Reig, M., Fernández-Checa, J. C., Marı́, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24673 · Cited by 71 · see citing works

Targeting cell death signalling in cancer: minimising ‘Collateral damage’

Fox, J. L., & MacFarlane, M. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.111 · Cited by 69 · see citing works

BH3 Profiling: A Functional Assay to Measure Apoptotic Priming and Dependencies

Fraser, C. S., Ryan, J. A., & Sarosiek, K. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8861-7_4 · Cited by 68 · see citing works

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D. E., Miles, W. O., Manos, M. P., Cidado, J. R., Secrist, J. P., Tron, A. E., Flaherty, K. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 68 · see citing works

It's time to die: BH3 mimetics in solid tumors

Kehr, S., & Vogler, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118987 · Cited by 67 · see citing works

An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma

Silva, A., Silva, M. C., Sudalagunta, P. R., Graeter, A. I., Jacobson, T., Collins, A., Nguyen, T., Song, J., Chen, D., Chen, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0502 · Cited by 66 · see citing works

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

Zervantonakis, I. K., Iavarone, C., Chen, H., Selfors, L. M., Palakurthi, S. S., Liu, J. F., Drapkin, R., Matulonis, U. A., Leverson, J. D., Sampath, D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00263-7 · Cited by 66 · see citing works

Targeting BCL-2 in B-cell lymphomas

Davids, M. S. (2017) · Blood · doi:10.1182/blood-2017-04-737338 · Cited by 65 · see citing works

Will liquid biopsies improve outcomes for patients with small-cell lung cancer?

Blackhall, F. H., Frese, K. K., Simpson, K., Kilgour, E., Brady, G., & Dive, C. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30455-8 · Cited by 65 · see citing works

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

Sperling, A. S., Burgess, M. W., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Slabicki, M. M., Sellar, R. S., Fink, E. C., Miller, P. G., et al. (2019) · Blood · doi:10.1182/blood.2019000789 · Cited by 65 · see citing works

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling

Seyfried, F., Demir, S., Hörl, R. L., Stirnweiß, F. U., Ryan, J. A., Scheffold, A., Villalobos-Ortiz, M., Boldrin, E., Zinngrebe, J., Enzenmüller, S., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1801-0 · Cited by 64 · see citing works

How to unleash mitochondrial apoptotic blockades to kill cancers?

Deng, J. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.08.005 · Cited by 64 · see citing works

High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors

Bhola, P. D., Ahmed, E., Guerriero, J. L., Sicińska, E., Su, E., Lavrova, E., Ni, J., Chipashvili, O., Hagan, T., Pioso, M. S., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aay1451 · Cited by 63 · see citing works

To Prime, or Not to Prime: That Is the QuestionPreprint

Potter, D. S., & Letai, A. G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030841 · Cited by 61 · see citing works

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Koch, R., Christie, A. L., Crombie, J. L., Palmer, A. C., Plana, D., Shigemori, K., Morrow, S. N., Scoyk, A. V., Wu, W., Brem, E. A., et al. (2018) · Blood · doi:10.1182/blood-2018-07-865527 · Cited by 60 · see citing works

Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cellsPreprint

Dai, H., Ding, H., Meng, X. W., Peterson, K. L., Schneider, P. A., Karp, J. E., & Kaufmann, S. H. (2015) · Genes & Development · doi:10.1101/gad.267997.115 · Cited by 60 · see citing works

Targeting BCL-2 in Hematologic Malignancies

Khan, N., & Kahl, B. S. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0560-7 · Cited by 59 · see citing works

Molecular Cell Biology of Apoptosis and Necroptosis in Cancer

Dillon, C. P., & Green, D. R. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_1 · Cited by 59 · see citing works

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Reimann, M., Schrezenmeier, J., Richter-Pechanska, P., Dolnik, A., Hick, T. P., Schleich, K., Cai, X., Fan, D. N. Y., Lohneis, P., Maßwig, S., et al. (2021) · Blood · doi:10.1182/blood.2020005244 · Cited by 59 · see citing works

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases

Risso, V., Lafont, É., & Gallo, M. L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04688-x · Cited by 58 · see citing works

Novel precision medicine approaches and treatment strategies in hematological malignancies

Rosenquist, R., Bernard, E., Erkers, T., Scott, D. W., Itzykson, R., Rousselot, P. H., Soulier, J., Hutchings, M., Östling, P., Cavelier, L. B., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13697 · Cited by 56 · see citing works

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

Dhandapani, M., & Goldman, A. J. (2017) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000356 · Cited by 54 · see citing works

Abstract 2837: Hitting the target: Dynamic BH3 profiling, a novel functional assay to predict chemotherapy response

Montero, J., Sarosiek, K., DeAngelo, J. D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U. A., Drapkin, R., & Letai, A. G. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-2837

Abstract 4569: Personalizing cancer therapy using dynamic BH3 profiling.

Montero, J., & Letai, A. G. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4569

BH3 Profiling - A Predictive Biomarker for Apoptotic Response to Chemotherapy

Letai, A. G. (2010) · Klinische Pädiatrie · doi:10.1055/s-0030-1270302

Initiation of Death Signaling Predicts Cytotoxic Response to Therapy

(2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2015-043

Abstract CN04-01: Poking cancer cells with BH3 profiling to personalize cancer therapy.

Montero, J., Chonghaile, T. N., Sarosiek, K., Ryan, J. A., Hogdal, L. J., & Letai, A. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-cn04-01